UCB (ENXTBR:UCB) - Stock Price, News & Analysis

UCB Stock Overview

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.

About the company

UCB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 52.5% below our estimate of its fair value

Earnings are forecast to grow 25.22% per year

Risk Analysis

No risks detected for UCB from our risk checks.

UCB SA Competitors

Financière de Tubize

ENXTBR:TUB

€4.1b

Otsuka Holdings

TSE:4578

JP¥3.5t

Royalty Pharma

NasdaqGS:RPRX

US$16.6b

Zhangzhou Pientzehuang Pharmaceutical

SHSE:600436

CN¥135.7b

Price History & Performance

Summary of all time highs, changes and price drops for UCB
Historical stock prices
Current Share Price	€120.80
52 Week High	€124.60
52 Week Low	€65.40
Beta	0.40
1 Month Change	4.68%
3 Month Change	41.12%
1 Year Change	41.68%
3 Year Change	54.24%
5 Year Change	70.81%
Change since IPO	39,488.90%

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

Is UCB (EBR:UCB) A Risky Investment?

Mar 27

Recent updates

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18

Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?

Feb 28

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 54% Above Its Share Price

Feb 10

What Makes UCB SA (EBR:UCB) A Great Dividend Stock?

Jan 20

Is UCB SA (EBR:UCB) Popular Amongst Institutions?

Jan 07

UCB (EBR:UCB) Is Growing Earnings But Are They A Good Guide?

Dec 23

With EPS Growth And More, UCB (EBR:UCB) Is Interesting

Dec 04

Shareholder Returns

	UCB	BE Pharmaceuticals	BE Market
7D	0.8%	2.3%	2.4%
1Y	41.7%	7.5%	-2.8%

Return vs Industry: UCB exceeded the Belgian Pharmaceuticals industry which returned 5.7% over the past year.

Return vs Market: UCB exceeded the Belgian Market which returned -3.3% over the past year.

Price Volatility

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement	3.7%
Pharmaceuticals Industry Average Movement	4.8%
Market Average Movement	3.7%
10% most volatile stocks in BE Market	7.7%
10% least volatile stocks in BE Market	2.5%

Stable Share Price: UCB's share price has been volatile over the past 3 months.

Volatility Over Time: UCB's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1925	8,767	Jean-Christophe Tellier	www.ucb.com

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome.

UCB SA Fundamentals Summary

How do UCB's earnings and revenue compare to its market cap?
UCB fundamental statistics
Market cap	€22.92b
Earnings (TTM)	€343.00m
Revenue (TTM)	€5.18b

66.8x

P/E Ratio

4.4x

P/S Ratio

Is UCB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UCB income statement (TTM)
Revenue	€5.18b
Cost of Revenue	€1.71b
Gross Profit	€3.48b
Other Expenses	€3.13b
Earnings	€343.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	1.81
Gross Margin	67.06%
Net Profit Margin	6.62%
Debt/Equity Ratio	32.1%

How did UCB perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

75%

Payout Ratio

Does UCB pay a reliable dividends?

See UCB dividend history and benchmarks

When do you need to buy UCB by to receive an upcoming dividend?
UCB dividend dates
Ex Dividend Date	Apr 26 2024
Dividend Pay Date	Apr 30 2024
Days until Ex dividend	0 days
Days until Dividend pay date	4 days

Does UCB pay a reliable dividends?

See UCB dividend history and benchmarks

UCB Stock Overview

Rewards

Risk Analysis

UCB SA Competitors

ENXTBR:TUB

€4.1b

TSE:4578

JP¥3.5t

NasdaqGS:RPRX

US$16.6b

SHSE:600436

CN¥135.7b

Price History & Performance

Recent News & Updates

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Recent updates

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA's (EBR:UCB) P/E Is On The Mark

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

First half 2022 earnings released

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year

Upcoming dividend of €0.91 per share

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome